Importantly, therapeutic strategies targeting the link between FOXA1 and the AR would be relevant in disease stages where AR signaling continues to be critical and where FOXA1 expression remains high, such as primary prostate cancer and CRPC (Figure 2). Here, AR is linked to prostate carcinoma.